The next generation weight-loss drugs could be launched next year, and they could be game-changing. The treatment, being dubbed "Ozempic 2.0," is a pill version the already widely-used Ozempic. Novo Nordisk, the pharmaceutical company developing the new tablet form, said its initial clinical trials revealed that Ozempic 2.0 "lowered weight an average 10.5 per cent". Rival company Eli Lilly is also working a pill. Its executive vice president, Kenneth Custer, said: "We are moving urgency global regulatory submissions to potentially meet the needs patients." The drugs are currently awaiting approval the Food and Drug Administration (FDA) the USA.
The game-changing medicines could make life much easier those hoping to shed weight, and people diabetes. Eli Lilly Chief Scientific Officer Dan Skovronsky said: "For the majority patients, this could be the main medicine that they need to control their type 2 diabetes as well as their obesity." Currently, the drug is administered the form a once-weekly injection an injectable pen. The pen has to be refrigerated. Mr Custer told reporters: "If approved, we are ready to offer a convenient, once-daily pill that can be scaled globally, removing barriers and redefining how obesity is treated the world." It is also likely that the new treatment will be cheaper.
